Project Grant R01HL183191
Award Date 7/15/26
Completion Date 4/30/30
Dollars Obligated $773K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $673,345 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct THRIVE, a mechanistic analysis of transfusion and hemolysis-related injury in pediatric extracorporeal membrane oxygenation (ECMO). The award funds analysis of data from the TITRE multicenter trial, which enrolled over 220 children on ECMO and collected time-resolved plasma...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $903,185 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL183614) to develop a Preemie ECMO System addressing respiratory failure in premature infants for whom extracorporeal membrane oxygenation is currently contraindicated. Work is performed at the University of Michigan in Ann Arbor, Michigan, with a period of performance through April 30,...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $466,500 for Project Grant R03HL177041 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a reproducible large animal model of acute lung injury (ALI) using swine to enable investigation of the therapeutic effects of extracorporeal membrane oxygenation (ECMO) on drivers of disease progression. ALI is a life-threatening condition with mortality...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Institute of Biomedical Imaging and Bioengineering awarded Colorado State University $231,000 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to optimize hemocompatible extracorporeal membrane oxygenation (ECMO) membranes through biomimetic surface modification and computational fluid dynamics. The research addresses blood clotting and platelet loss in hollow fiber membrane oxygenators used in...
- The National Heart, Lung, and Blood Institute awarded The Washington University $759,584 on September 1, 2026, for research developing high-density diffuse optical tomography (HD-DOT) methods for bedside neuroimaging of brain health in children undergoing extracorporeal membrane oxygenation (ECMO) support. This award is made under the Cardiovascular Diseases Research program (CFDA 93.837). The research aims to advance HD-DOT imaging to evaluate functional connectivity and cerebral oxygenation in...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $767,953 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomimetic engineered heart valve leaflets that improve function and tissue remodeling. Work extends through March 31, 2030, and is performed in Pittsburgh, Pennsylvania. The project addresses clinical failures in tissue-engineered heart valves (TEHVs) deployed in pediatric patients, where pulmonary...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received $874,997 in federal funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project grant awarded on September 15, 2025, with completion targeted by August 31, 2026. The project delivers a prospective clinical trial evaluating personalized oxygen therapy targets for mechanically ventilated critically ill adults. The research applies...
- The National Heart Lung and Blood Institute awarded Regents of the University of Michigan $771,350 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an endovascular vortex ultrasound thrombolysis system for treatment of pulmonary embolism. The project will design, fabricate, and characterize a vortex ultrasound transducer integrated into a 9-French catheter to achieve rapid (under 30 minutes) and safe thrombolysis with minimal lytic agent and...